BG63150B1 - Метод за лечение на травматично мозъчно увреждане - Google Patents

Метод за лечение на травматично мозъчно увреждане Download PDF

Info

Publication number
BG63150B1
BG63150B1 BG102480A BG10248098A BG63150B1 BG 63150 B1 BG63150 B1 BG 63150B1 BG 102480 A BG102480 A BG 102480A BG 10248098 A BG10248098 A BG 10248098A BG 63150 B1 BG63150 B1 BG 63150B1
Authority
BG
Bulgaria
Prior art keywords
treatment
tetrahydro
ethyl
methylpyridine
cerebral
Prior art date
Application number
BG102480A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102480A (en
Inventor
Brian Pike
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of BG102480A publication Critical patent/BG102480A/xx
Publication of BG63150B1 publication Critical patent/BG63150B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BG102480A 1995-11-06 1998-05-22 Метод за лечение на травматично мозъчно увреждане BG63150B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK123295 1995-11-06
PCT/DK1996/000458 WO1997017074A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Publications (2)

Publication Number Publication Date
BG102480A BG102480A (en) 1999-01-29
BG63150B1 true BG63150B1 (bg) 2001-05-31

Family

ID=8102484

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102480A BG63150B1 (bg) 1995-11-06 1998-05-22 Метод за лечение на травматично мозъчно увреждане

Country Status (18)

Country Link
EP (1) EP0866706A1 (de)
JP (1) JPH11514654A (de)
KR (1) KR19990067353A (de)
AU (1) AU706594B2 (de)
BG (1) BG63150B1 (de)
BR (1) BR9611396A (de)
CA (1) CA2234824A1 (de)
CZ (1) CZ287441B6 (de)
EA (1) EA000531B1 (de)
HU (1) HUP9901051A2 (de)
IS (1) IS4726A (de)
NO (1) NO982036L (de)
NZ (1) NZ321546A (de)
PL (1) PL326490A1 (de)
SK (1) SK58198A3 (de)
TR (1) TR199800801T2 (de)
WO (1) WO1997017074A1 (de)
ZA (1) ZA969320B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013096A1 (es) * 1997-07-01 2000-12-13 Lundbeck & Co As H Sal de adicion de acido maleico de 5-(2-etil-2-h-tetrazol-5-il)-1-metil- 1,2,3,6-tetrahidropiridina, composicion farmaceutica que la contiene, su usoen terapia y metodo de preparacion de la misma.
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives

Also Published As

Publication number Publication date
BG102480A (en) 1999-01-29
EP0866706A1 (de) 1998-09-30
PL326490A1 (en) 1998-09-28
BR9611396A (pt) 1999-07-13
AU7490096A (en) 1997-05-29
CA2234824A1 (en) 1997-05-15
EA000531B1 (ru) 1999-10-28
EA199800434A1 (ru) 1998-10-29
NO982036D0 (no) 1998-05-05
JPH11514654A (ja) 1999-12-14
CZ138998A3 (cs) 1998-10-14
AU706594B2 (en) 1999-06-17
IS4726A (is) 1998-04-27
NZ321546A (en) 2000-12-22
MX9803432A (es) 1998-09-30
TR199800801T2 (xx) 1998-08-21
NO982036L (no) 1998-06-25
SK58198A3 (en) 1998-10-07
WO1997017074A1 (en) 1997-05-15
CZ287441B6 (en) 2000-11-15
KR19990067353A (ko) 1999-08-16
ZA969320B (en) 1997-05-30
HUP9901051A2 (hu) 2000-03-28

Similar Documents

Publication Publication Date Title
AT395374B (de) Pharmazeutisches praeparat
DE69631134T2 (de) Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole
DE69911259T2 (de) Tricyclische benzodiazepine als vasopressin antagonisten
DE60129934T2 (de) Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie
DE3686622T2 (de) Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.
RU2469723C2 (ru) Лекарственное средство, содержащее производное карбостирила и донепезил, для лечения болезни альцгеймера
US6297262B1 (en) Treatment of schizophrenia and psychosis
BG63150B1 (bg) Метод за лечение на травматично мозъчно увреждане
KR950010148B1 (ko) 중독증 치료용 의약품
DE3782028T2 (de) Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.
DE2914511A1 (de) 4-chinolinylaminobenzoylpiperidine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
JPH07504915A (ja) ムスカリン拮抗物質投与による，哺乳動物の眼における眼内圧低下法
US20060135507A1 (en) Therapeutic agent for overactive bladder involved in aging
CZ20013812A3 (cs) Pouľití saredutantu a jeho farmaceuticky přijatelných solí pro přípravu léčiva pouľitelného k léčení nebo prevenci poruch nálady, poruch adaptace nebo stavů úzkosti a deprese
US20060269598A1 (en) Antihistaminic/Decongestant/Anticholinergic Compositions and Methods of Use
PL175375B1 (pl) Środek farmaceutyczny przeciwalergiczny i sposób wytwarzania środka farmaceutycznego przeciwalergicznego
DE60308378T2 (de) Nicht-Hormonal Verfahren zur männlichen Verhütung
ES2295588T3 (es) Uso de ambroxol para el tratamiento de dolores cronicos.
US6610720B2 (en) Method for treating or preventing emesis
US5574041A (en) Use of spiperone derivatives as immunosuppressant agents
WO2000032199A1 (de) Verwendung von galanthamin und galanthaminderivaten bei akuten funktionellen hirnschäden
HU200098B (en) Process for producing pharmaceutical compositions for treating peptic ulcers
US20060269597A1 (en) Tannate Compositions and Methods of Use for the Treatment of Respiratory Tract Conditions
EP0690715B1 (de) Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind
MXPA98003432A (en) Treatment of traumat cerebral damage